AIMS: Vedolizumab (VDZ) prevents migration of activated leucocytes into inflamed mucosa. This study aimed to assess the patterns of serum cytokines in ulcerative colitis (UC) patients at baseline and during VDZ treatment, and to investigate their association with mucosal healing and clinical remission. METHODS: We enrolled consecutive UC patients eligible for treatment with VDZ. A panel of serum cytokines were measured by fluorescence assay at weeks 0, 6 and 22. Colonoscopy was performed at baseline and week 54, to evaluate mucosal healing. The time trends of serum cytokines were analysed by log-linear mixed effect models, and their prognostic accuracy was evaluated by logistic regression. RESULTS: Out of 27 patients included in the analysis, at week 54 mucosal healing was achieved in 12 (44%) and clinical remission in 17 (63%). Mucosal healing was associated with higher interleukin (IL)-8 values at baseline and with significant decrease in IL-6 and IL-8 levels over the first 6 weeks. A significant reduction of IL-6 and IL-8 levels over the first 6 weeks of treatment was associated also with clinical remission. Logistic models including, among the predictors, IL-6 and IL-8 at baseline and their changes over the first 6 weeks of treatment had 83% sensitivity and 87% specificity to predict mucosal healing, and 82% sensitivity and 90% specificity to predict clinical remission. CONCLUSION: In UC patients, the serum patterns of IL-6 and IL-8 at baseline and over the first 6 weeks of treatment with VDZ could be useful to predict therapeutic outcome.
AIMS: Vedolizumab (VDZ) prevents migration of activated leucocytes into inflamed mucosa. This study aimed to assess the patterns of serum cytokines in ulcerative colitis (UC) patients at baseline and during VDZ treatment, and to investigate their association with mucosal healing and clinical remission. METHODS: We enrolled consecutive UCpatients eligible for treatment with VDZ. A panel of serum cytokines were measured by fluorescence assay at weeks 0, 6 and 22. Colonoscopy was performed at baseline and week 54, to evaluate mucosal healing. The time trends of serum cytokines were analysed by log-linear mixed effect models, and their prognostic accuracy was evaluated by logistic regression. RESULTS: Out of 27 patients included in the analysis, at week 54 mucosal healing was achieved in 12 (44%) and clinical remission in 17 (63%). Mucosal healing was associated with higher interleukin (IL)-8 values at baseline and with significant decrease in IL-6 and IL-8 levels over the first 6 weeks. A significant reduction of IL-6 and IL-8 levels over the first 6 weeks of treatment was associated also with clinical remission. Logistic models including, among the predictors, IL-6 and IL-8 at baseline and their changes over the first 6 weeks of treatment had 83% sensitivity and 87% specificity to predict mucosal healing, and 82% sensitivity and 90% specificity to predict clinical remission. CONCLUSION: In UCpatients, the serum patterns of IL-6 and IL-8 at baseline and over the first 6 weeks of treatment with VDZ could be useful to predict therapeutic outcome.
Authors: Sebastian Zeissig; Elisa Rosati; C Marie Dowds; Konrad Aden; Philip C Rosenstiel; Andre Franke; Stefan Schreiber; Johannes Bethge; Berenice Schulte; Wei Hung Pan; Neha Mishra; Maaz Zuhayra; Marlies Marx; Maren Paulsen; Anne Strigli; Claudio Conrad; Dörthe Schuldt; Anupam Sinha; Henriette Ebsen; Sabin-Christin Kornell; Susanna Nikolaus; Alexander Arlt; Dieter Kabelitz; Mark Ellrichmann; Ulf Lützen Journal: Gut Date: 2018-05-05 Impact factor: 23.059
Authors: Luisa Guidi; Daniela Pugliese; Tommaso Panici Tonucci; Lorenzo Bertani; Francesco Costa; Giuseppe Privitera; Barbara Tolusso; Clara Di Mario; Eleonora Albano; Gherardo Tapete; Elisa Gremese; Alfredo Papa; Antonio Gasbarrini; Gian Ludovico Rapaccini; Alessandro Armuzzi Journal: United European Gastroenterol J Date: 2019-09-03 Impact factor: 4.623
Authors: Brian G Feagan; Paul Rutgeerts; Bruce E Sands; Stephen Hanauer; Jean-Frédéric Colombel; William J Sandborn; Gert Van Assche; Jeffrey Axler; Hyo-Jong Kim; Silvio Danese; Irving Fox; Catherine Milch; Serap Sankoh; Tim Wyant; Jing Xu; Asit Parikh Journal: N Engl J Med Date: 2013-08-22 Impact factor: 91.245
Authors: Maria Gloria Mumolo; Lorenzo Bertani; Linda Ceccarelli; Gabriella Laino; Giorgia Di Fluri; Eleonora Albano; Gherardo Tapete; Francesco Costa Journal: World J Gastroenterol Date: 2018-09-07 Impact factor: 5.742
Authors: Gian Paolo Caviglia; Chiara Rosso; Francesco Stalla; Martina Rizzo; Alessandro Massano; Maria Lorena Abate; Antonella Olivero; Angelo Armandi; Ester Vanni; Ramy Younes; Sharmila Fagoonee; Rinaldo Pellicano; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-03-15 Impact factor: 4.241
Authors: Lorenzo Bertani; Gian Paolo Caviglia; Luca Antonioli; Rinaldo Pellicano; Sharmila Fagoonee; Marco Astegiano; Giorgio Maria Saracco; Elisabetta Bugianesi; Corrado Blandizzi; Francesco Costa; Davide Giuseppe Ribaldone Journal: J Clin Med Date: 2020-05-02 Impact factor: 4.241